Completed PHASE2 INTERVENTIONAL 2-arm NCT01157936

Hyperuricemia on Hypertension and Metabolic Syndrome

Effect of Hyperuricemia Treatment on Hypertension and Metabolic Syndrome

Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez

Conditions Hepatic Enzymes Metabolic Syndrome Parameters Systolic and Diastolic Blood Pressure Levels Uric Acid Levels

Updated 6 times since 2017 Last updated: Jul 23, 2014 Started: Jul 31, 2010 Primary completion: Feb 28, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01157936, this PHASE2 trial focuses on Hepatic Enzymes and Metabolic Syndrome Parameters and remains completed. Sponsored by Instituto Nacional de Cardiologia Ignacio Chavez, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Instituto Nacional de Cardiologia Ignacio Chavez
National Council of Science and Technology, Mexico

Data source: Instituto Nacional de Cardiologia Ignacio Chavez

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• México, Mexico